GET DAILY SIGNALSVeradermics (MANE): Can the Stock Reach Its $170 Analyst Target After a Strong Run?
Key Takeaways
- The central target of $170 is the arithmetic mean of six verified analyst price targets, rounded from a calculated mean of $166.
- At the latest verified price of $143.95, reaching $170 would require an upside of roughly 18% — a substantial but not extreme move.
- Individual analyst targets range from $150 to $182, and all six carry Buy or Outperform ratings, reflecting a broad "Strong Buy" posture.
- Key supports include positive mid-stage clinical data, a large addressable hair-loss market, and a sizable cash balance, while the biggest risks are binary trial readouts, a pre-revenue profile, and elevated short interest.
- The stock has climbed more than 300% year-to-date and trades near its 52-week high, which raises the bar for further gains.
- Investors can review Major News, Today's Price Move, the Forecast, and upcoming Earnings on dedicated pages to track the factors behind the target.
- Readers can also explore Trending AI Robots for automated approaches to monitoring this and other tickers.
What the Analyst Targets Reveal
Veradermics has only been public since early 2026, so coverage is still developing, but six firms with attributable targets and dates were reviewed for this calculation. The most recent are Leerink Partners at $150 (raised from $135 on November 9, 2026), Citigroup at $160, Needham at $164, Jefferies at $182, LifeSci Capital at $170, and B. Riley Securities at $170. These produce a mean of $166, rounded here to a clean $170 central target, within a $150–$182 range. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Every rating is a Buy or Outperform, and several targets were raised during 2026 after clinical data readouts, indicating upward revision momentum rather than a single outlier-driven view. Some aggregators, including S&P Global data, report a slightly higher average near $173 with a high above $200, underscoring that the range is wide and that no figure is a guarantee. The dispersion — from $150 to $182 — reflects genuine disagreement about how much of the hair-loss opportunity is already priced in.
Current Market Position and Path Toward the Target
As of the most recent close, MANE traded at $143.95, giving it a market capitalization of roughly $6 billion. Moving to $170 requires about 18% appreciation, a substantial move for a company that has already surged more than 300% year-to-date and trades just below its 52-week high of $146.58. Because Veradermics has no approved product revenue, it has no meaningful P/E (price-to-earnings) ratio; the stock is valued on pipeline potential, milestone catalysts, and cash on hand rather than current earnings.
What Could Support a Move Toward the Target
The core thesis is VDPHL01. In July 2026 the company reported positive Phase 2 results from Study 207 in female pattern hair loss, and it has presented subgroup data from the Phase 2/3 Study 302 in males. Androgenetic alopecia affects a very large patient population, and an oral, non-hormonal option would address an underserved market, supporting a substantial commercial opportunity. Veradermics also holds roughly $820 million in cash, providing runway through upcoming readouts without immediate financing pressure. Rising analyst targets through 2026 reflect growing conviction in the lead program, a factor that has historically accompanied sustained momentum in clinical-stage biotech.
What Could Prevent the Target From Being Reached
The principal risk is binary clinical risk: a disappointing or ambiguous result from the upcoming Phase 2/3 Study 306 readout in female pattern hair loss could rapidly reprice the stock. Veradermics is pre-revenue with a net loss of about $104 million over the trailing twelve months, so there is no earnings floor beneath the valuation. Competition in dermatology and aesthetic medicine is intense, regulatory approval is uncertain, and future capital raises could dilute existing shareholders. Short interest of roughly 15.6% of float adds volatility, and a roughly $6 billion valuation for a company without marketed products leaves limited margin for error.
Technical Levels and Market Structure
MANE's 52-week range runs from $32.00 to $146.58, and the stock is trading just beneath that upper bound, near all-time highs. The $146–$150 zone is a meaningful near-term resistance area that roughly coincides with the lowest analyst target of $150. A sustained move above it would put $160 and then the $170 objective in view, while the recent consolidation range around $130–$145 provides a support level to monitor on any pullback. The $170 area also functions as a psychological round-number level aligned with several analyst targets.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though no single timeframe is stated uniformly across the six firms reviewed. The most important near-term items are the Phase 2/3 Study 306 readout for VDPHL01 in female pattern hair loss, the company's next earnings report, and any additional analyst target revisions following data disclosures. Investors should also watch cash burn, insider activity, and shifts in short interest, all of which can move a thinly covered, catalyst-driven stock sharply.
Using AI Daily Buy/Sell Signals for Monitoring
I often rely on Tickeron's AI Daily Buy/Sell Signals to stay on top of names like this. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market shifts. For a catalyst-driven stock such as MANE, it helps surface timely observations without replacing personal analysis. This approach has become a regular part of my process for tracking event-heavy names efficiently.
Final Assessment
The $170 central target is the rounded average of six verified analyst targets ranging from $150 to $182, and it sits roughly 18% above the latest price of $143.95. The strongest supports are positive VDPHL01 data, a large addressable market, ample cash, and a uniformly bullish analyst base. The principal obstacles are the binary nature of upcoming trial readouts, a pre-revenue business model, an elevated valuation, and heavy short interest. Whether MANE reaches $170 will likely hinge on the next clinical catalysts rather than on valuation arithmetic alone, and no outcome should be treated as assured.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for MANE turns positive, indicating new upward trend
MANE saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator turned positive. In 13 of the 14 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MANE just turned positive on November 10, 2026. Looking at past instances where MANE's MACD turned positive, the stock continued to rise in 7 of 7 cases over the following month. The odds of a continued upward trend are 90%.
MANE moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where MANE advanced for three days, in 42 of 47 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Aroon Indicator entered an Uptrend today. In 26 of 28 cases where MANE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for MANE moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 9 similar instances where the indicator moved out of overbought territory. In 7 of the 9 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MANE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
MANE broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.127) is normal, around the industry mean (3.498). P/E Ratio (-55.597) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. MANE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MANE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What does notional value mean?
What Part of the Contribution into My IRA is Tax-Deductible?
What Should I Do With a Lump-Sum Distribution From My Cash-Balance Plan?
How Do You Understand Tax Returns: Importance, Retention, and Deductions?
AI Bot Trading: Top 5 Day Traders, Virtual Accounts, on November 14, 2024
General Information
Industry Biotechnology
Advertisement